News

BaxHTN trial results showed baxdrostat led to a significant reduction of systolic blood pressure compared to placebo, with a favorable safety profile.

Treatment with baxdrostat resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia in the phase 2a SPARK trial.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

Discover cutting-edge insights on schizophrenia, mood disorders, and digital therapeutics at the 2025 Southern California Psychiatry Conference.

Majcher discusses innovations in ocular imaging and the importance of educating patients on early warning signs of myopia to halt disease progression.

Thomas discusses emerging therapies, new technologies, and the reform needed to help these new developments reach the patients in need of them.

Study findings highlight the cost-effectiveness of more frequent HCV testing among people who inject drugs compared with no testing and less frequent testing.

Discover how recent advancements in biologic therapies transform severe asthma treatment, emphasizing personalized care and the importance of biomarker-driven decisions.

The FDA also announced an updated PDUFA date of December 13, 2025 for the self-administered nasal spray.

Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.

Sandforth discussed his research that found that early prediabetes remission conferred greater protective effects against T2D than later remission.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Nontargeted screening identified more HCV infections than targeted screening, but both approaches led to minimal linkage to care and SVR12.

New research highlights significant declines in cardiovascular screenings for U.S. adults with disabilities during the COVID-19 pandemic, revealing ongoing healthcare disparities.

Landela’s research on an impoverished community in South Africa encourages clinicians to help similar populations get the care they need.

Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Nguyen spoke to the importance of being aware of heightened stress, anxiety, and depression due to myopia’s long-term treatment requirements.